Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;31(5):312-317.
doi: 10.1097/ICU.0000000000000680.

Artificial intelligence for retinopathy of prematurity

Affiliations
Review

Artificial intelligence for retinopathy of prematurity

Rebekah H Gensure et al. Curr Opin Ophthalmol. 2020 Sep.

Abstract

Purpose of review: In this article, we review the current state of artificial intelligence applications in retinopathy of prematurity (ROP) and provide insight on challenges as well as strategies for bringing these algorithms to the bedside.

Recent findings: In the past few years, there has been a dramatic shift from machine learning approaches based on feature extraction to 'deep' convolutional neural networks for artificial intelligence applications. Several artificial intelligence for ROP approaches have demonstrated adequate proof-of-concept performance in research studies. The next steps are to determine whether these algorithms are robust to variable clinical and technical parameters in practice. Integration of artificial intelligence into ROP screening and treatment is limited by generalizability of the algorithms to maintain performance on unseen data and integration of artificial intelligence technology into new or existing clinical workflows.

Summary: Real-world implementation of artificial intelligence for ROP diagnosis will require massive efforts targeted at developing standards for data acquisition, true external validation, and demonstration of feasibility. We must now focus on ethical, technical, clinical, regulatory, and financial considerations to bring this technology to the infant bedside to realize the promise offered by this technology to reduce preventable blindness from ROP.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

M.F.C. is a Consultant for Novartis (Basel, Switzerland), and an initial member of InTeleretina (Honolulu, HI). J.P.C. and M.F.C. may receive royalties from related technology licensed to BostonAI (Boston, MA).

References

    1. Solebo AL, Teoh L, Rahi J. Epidemiology of blindness in children. Arch Dis Child 2017; 102:853–857. - PubMed
    1. Haines L, Fielder AR, Scrivener R, et al. Retinopathy of prematurity in the UK I: the organisation of services for screening and treatment. Eye (Lond) 2002; 16:33–38. - PubMed
    1. Campbell JP, Ryan MC, Lore E, et al. Diagnostic discrepancies in retinopathy of prematurity classification. Ophthalmology 2016; 123:1795–1801. - PMC - PubMed
    1. Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al., BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group. Oxygen saturation and outcomes in preterm infants. N Engl J Med 2013; 368:2094–2104. - PubMed
    1. Ting DSW, Cheung CY, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA 2017; 318: 2211–2223. - PMC - PubMed